Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk

Heart Rhythm. 2020 Sep;17(9):1480-1486. doi: 10.1016/j.hrthm.2020.07.001. Epub 2020 Jul 3.

Abstract

(Hydroxy)chloroquine ((H)CQ) is being investigated as a treatment for COVID-19, but studies have so far demonstrated either no or a small benefit. However, these studies have been mostly performed in patients admitted to the hospital and hence likely already (severely) affected. Another suggested approach uses prophylactic (H)CQ treatment aimed at preventing either severe acute respiratory syndrome coronavirus 2 infection or the development of disease. A substantial number of clinical trials are planned or underway aimed at assessing the prophylactic benefit of (H)CQ. However, (H)CQ may lead to QT prolongation and potentially induce life-threatening arrhythmias. This may be of particular relevance to patients with preexisting cardiovascular disease and those taking other QT-prolonging drugs. In addition, it is known that a certain percentage of the population carries genetic variant(s) that reduces their repolarization reserve, predisposing them to (H)CQ-induced QT prolongation, and this may be more relevant to female patients who already have a longer QT interval to start with. This review provides an overview of the current evidence on (H)CQ therapy in patients with COVID-19 and discusses different strategies for prophylactic (H)CQ therapy (ie, preinfection, postexposure, and postinfection). In particular, the potential cardiac effects, including QT prolongation and arrhythmias, will be addressed. Based on these insights, recommendations will be presented as to which preventive measures should be taken when giving (H)CQ prophylactically, including electrocardiographic monitoring.

Keywords: Arrhythmia; COVID-19; Chloroquine; ECG; Hydroxychloroquine; Prophylaxis; QT; Recommendations; SARS-CoV-2; Torsades de pointes.

Publication types

  • Review

MeSH terms

  • Antimalarials / therapeutic use*
  • Arrhythmias, Cardiac / epidemiology*
  • Betacoronavirus*
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / complications
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / prevention & control*
  • Humans
  • Hydroxychloroquine / therapeutic use*
  • Pandemics / prevention & control*
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / prevention & control*
  • SARS-CoV-2

Substances

  • Antimalarials
  • Hydroxychloroquine